Rising Monkeypox Cases and Decreased Smallpox Immunity Raise Concerns of Potential Pandemic

Faghir Ganji, Monireh; Jahanian, Sepideh; Khezri, Rozhan

doi:10.30699/ijmm.18.2.132

year 18, Issue 2 (March - April 2024) Iran J Med Microbiol 2024, 18(2): 132-134 | Back to browse issues page

‎ 10.30699/ijmm.18.2.132

Mendeley

Zotero

RefWorks

Faghir Ganji M, Jahanian S, Khezri R. Rising Monkeypox Cases and Decreased Smallpox Immunity Raise Concerns of Potential Pandemic. Iran J Med Microbiol 2024; 18 (2) :132-134
URL: http://ijmm.ir/article-1-2322-en.html

Rising Monkeypox Cases and Decreased Smallpox Immunity Raise Concerns of Potential Pandemic

Monireh Faghir Ganji¹

, Sepideh Jahanian²

, Rozhan Khezri³

1- Student Research Committee, Iran University of Medical Sciences, Tehran, Iran
2- Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, United States
3- Student Research Committee, Iran University of Medical Sciences, Tehran, Iran , khezri.rojan@yahoo.com

Abstract: (1167 Views)

Monkeypox can spread rapidly among humans. Over 10,000 new Monkeypox virus(MPV) cases were reported between May 4 and July 12, 2022. It is transmitted through contact with infected animals, respiratory droplets, and shared items. Symptoms are similar to smallpox but milder. Smallpox is caused by variola virus (VAV). The halt in smallpox vaccinations has left 70% of the world unvaccinated against related viruses. Preliminary genetic data shows differences between VAV and MPV. Though their core genomic regions are nearly identical, the end genomic regions exhibit significant differences in factors like virulence and host domain. Immunity against VAV also protects against MPV; the smallpox vaccine offers strong resistance to MPV in around 85% of individuals. However, immunity against smallpox has decreased over the years, leading to increased susceptibility to monkeypox in unvaccinated adults aged 21 to 40, and indicating a risk of MPV transmission and higher illness prevalence in older populations. The increase in monkeypox cases, changing transmission patterns, the decreased immunity against smallpox, and the potential for bioterrorism are all reasons to monitor the situation closely and implement measures to contain these viruses.

Keywords: Monkeypox, Potential Pandemic, Smallpox, World

Full-Text [PDF 354 kb] (434 Downloads) | | Full-Text (HTML) (174 Views)

Type of Study: Letter to the Editor | Subject: Microbial Immunology
Received: 2024/02/20 | Accepted: 2024/05/10 | ePublished: 2024/05/25

References

1. Khezri R, Nikbakht HA, Aljalili S, Ghelichi-Ghojogh M. Is it possible to eradicate the covid-19 or not?. New Microbes New Infect. 2022;49-50:101023. [DOI:10.1016/j.nmni.2022.101023] [PMID] [PMCID]

2. Khezri R, Rezaei F, Motevalli FD. Covid-19 pandemic and risk of Myopia. Ann Med Surg. 2022;79. [DOI:10.1016/j.amsu.2022.103944] [PMID] [PMCID]

3. Meyer H, Perrichot M, Stemmler M, Emmerich P, Schmitz H, Varaine F, et al. Outbreaks of disease suspected of being due to human monkeypox virus infection in the Democratic Republic of Congo in 2001. J Clin Microbiol. 2002;40(8):2919-21. [DOI:10.1128/JCM.40.8.2919-2921.2002] [PMID] [PMCID]

4. Rizk JG, Lippi G, Henry BM, Forthal DN, Rizk Y. Prevention and treatment of monkeypox. Drugs. 2022;82(9):957-63. [DOI:10.1007/s40265-022-01742-y] [PMID] [PMCID]

5. Khezri R, Rezaei F, Jahanian S, ZareiVenovel M. The importance of differentiating monkeypox from chickenpox: possible response for better preparedness. Health Sci Monit. 2023;2(4):258-61. [DOI:10.61186/hsm.2.4.258]

6. Strassburg MA. The global eradication of smallpox. Am J Infect Control. 1982;10(2):53-9. [DOI:10.1016/0196-6553(82)90003-7] [PMID]

7. Almehmadi M, Allahyani M, Alsaiari AA, Alshammari MK, Alharbi AS, Hussain KH, et al. A glance at the development and patent literature of tecovirimat: the first-in-class therapy for emerging monkeypox outbreak. Viruses. 2022;14(9):1870. [DOI:10.3390/v14091870] [PMID] [PMCID]

8. Berche P. Life and death of smallpox. La Presse Médicale. 2022;51(3):104117. [DOI:10.1016/j.lpm.2022.104117] [PMID]

9. Sang Y, Zhang Z, Liu F, Lu H, Yu C, Sun H, et al. Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus. Signal Transduct Target Ther.2023;8(1):172. [DOI:10.1038/s41392-023-01432-5] [PMID] [PMCID]

10. Kumar N, Acharya A, Gendelman HE, Byrareddy SN. The 2022 outbreak and the pathobiology of the monkeypox virus. J Autoimmun. 2022;131:102855. [DOI:10.1016/j.jaut.2022.102855] [PMID] [PMCID]

11. Akter F, Hasan TB, Alam F, Das A, Afrin S, Maisha S, et al. Effect of prior immunisation with smallpox vaccine for protection against human Mpox: a systematic review. Rev Med Virol. 2023;33(4):e2444. [DOI:10.1002/rmv.2444] [PMID]

12. Shchelkunov SN, Totmenin AV, Babkin IV, Safronov PF, Ryazankina OI, Petrov NA, et al. Human monkeypox and smallpox viruses: genomic comparison. FEBS lett. 2001;509(1):66-70. [DOI:10.1016/S0014-5793(01)03144-1] [PMID]

13. Jiang RM, Zheng YJ, Zhou L, Feng LZ, Ma L, Xu BP, et al. Diagnosis, treatment, and prevention of monkeypox in children: an experts' consensus statement. World J Clin Pediatr. 2023;19(3):231-42. [DOI:10.1007/s12519-022-00624-3] [PMID] [PMCID]

14. Berche P. The threat of smallpox and bioterrorism. Trends Microbiol. 2001;9(1):15-8. [DOI:10.1016/S0966-842X(00)01855-2] [PMID]